Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
0.3340
-0.0261 (-7.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
August 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
August 28, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
August 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
August 19, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
August 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Updates Regarding the Status of the AutoMax Merger
August 14, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
July 08, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Secures Strategic Advantage with Grant of European Patent
May 31, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc to Acquire AutoMax
April 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
March 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
March 21, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
March 18, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
March 14, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
March 12, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
March 08, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
March 07, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
March 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
February 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
January 24, 2024
From
SciSparc Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.